PDF(Sci-hub)
Abstract：
Increasing epidemiological studies have focused on the associations between interleukin-6 (IL-6) gene -174G>C polymorphism and atherosclerotic diseases, but the results are still controversial. This meta-analysis was designed to identify whether this association exists. PubMed, Embase, Web of Science, Cochrane database, Clinicaltrials.gov and Current Controlled Trials, Chinese Clinical Trial Registry, CBMdisc, CNKI and Google Scholar were searched to get the genetic association studies. The crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were used to estimate the association between the IL-6 gene -174G>C polymorphism and atherosclerosis ( AS ) risk. The subgroup analyses were made on the following: ethnicity, atherosclerotic diseases and source of controls. Finally, 50 studies (15,029 cases and 18,485 controls) were included in this meta-analysis. Overall, no significant association was found between the IL-6 gene -174G>C polymorphism and AS risk (for C allele vs. G allele: OR=1.02, 95% CI=0.94-1.11, p=0.64; for C/C vs. G/G: OR=1.01, 95% CI=0.85-1.21, p=0.88; for C/C vs. C/G+G/G: OR=0.97, 95% CI=0.84-1.12, p=0.68; for C/C+C/G vs. G/G: OR=1.07, 95% CI=0.97-1.17, p=0.18). In the subgroup analyses, significant associations were found between the IL-6 gene -174G>C polymorphism and AS in non-Caucasian group (for CC+CG vs. GG: OR=1.22, 95% CI=1.06-1.41, p=0.005), other atherosclerotic diseases group (for C allele vs. G allele: OR =0.75, 95% CI=0.61-0.93, p=0.008; for C/C vs. G/G: OR=0.56, 95% CI=0.38-0.81, p=0.002; for C/C vs. C/G+G/G: OR=0.60, 95% CI=0.45-0.79, p=0.0004) and population-based group (for C allele vs. G allele: OR=1.09, 95% CI=1.00-1.18, p=0.04; for CC+CG vs. GG: OR=1.15, 95% CI=1.04-1.27, p=0.005). In summary, the present meta-analysis suggests that the IL-6 gene -174G C polymorphism is associated with the susceptibility to AS. However, due to the high heterogeneity in the meta-analysis, the results should be interpreted with caution.
摘要：
越来越多的流行病学研究集中在白细胞介素-6（IL-6）基因-174G>C多态性与动脉粥样硬化疾病之间的关系。但结果仍有争议。这项荟萃分析旨在确定这种关联是否存在。PubMed,Embase,WebofScience,Cochrane数据库,Clinicaltrials.gov和电流控制试验，中国临床试验注册中心,CBMdisc,通过CNKI和谷歌学者进行遗传关联研究。使用粗比值比（ORs）及其相应的95％置信区间（CIs）来估计IL-6基因-174G>C多态性与动脉粥样硬化（AS）风险之间的关联。进行了以下亚组分析：种族，动脉粥样硬化疾病和控制源。最后,50项研究（15,029例和18,485例对照）被纳入该荟萃分析。总的来说,IL-6基因-174G>C多态性与AS风险之间没有发现显着关联（对于C等位基因与G等位基因：OR=1.02，95％CI=0.94-1.11，p=0.64；C/Cvs.G/G：OR=1.01，95%CI=0.85-1.21，p=0.88；C/C与C/G+G/G：OR=0.97，95%CI=0.84-1.12，p=0.68；C/C+C/G与G/G：OR=1.07，95%CI=0.97-1.17，p=0.18）。在亚组分析中，在非高加索人群中，IL-6基因-174G>C多态性与AS之间存在显着关联（对于CCCG与GG：OR=1.22，95%CI=1.06-1.41，p=0.005），其他动脉粥样硬化性疾病组(对于C等位基因与G等位基因：OR=0.75，95％CI=0.61-0.93，p=0.008；C/Cvs.G/G：OR=0.56，95％CI=0.38-0.81，p=0.002；C/C与C/G+G/G：OR=0.60，95%CI=0.45-0.79，p=0.0004）和基于人群的组（对于C等位基因与G等位基因：OR=1.09，95％CI=1.00-1.18，p=0.04；对于CCCG与GG：OR=1.15，95%CI=1.04-1.27，p=0.005）。总之,本荟萃分析提示IL-6基因-174GC多态性与AS易感性相关。然而,由于荟萃分析的高度异质性，结果应谨慎解释.
